Syneron Bio
Both parties publicly confirmed the AstraZeneca collaboration. A 2026 financing announcement states that proceeds will advance the pipeline into clinical development; specific human oral PK data were not disclosed.
Corporate information
- Company entity
- Syneron Bio／元思生肽
- Headquarters / principal office
- No verified public location identified
- Founded
- 2022 ↗
- Ownership / capital status
- PrivateSeries B (latest disclosure identified) ↗
- Official corporate reference
- https://www.syneronbio.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
- Latest financing / award identified
- 2026-04-03 · Series B · $150 million ↗
The company states that the round closed on 2026-03-31; the announcement was published April 3.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Public evidence snapshot
The company's official Chinese name is 元思生肽 and its English name is Syneron Bio; 原思生肽 was a previous search alias.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.